RSS

STA Pharmaceutical

Partner of STA Pharmaceutical, Ascletis, has been granted approval by the Chinese Food and Drug Administration (CFDA) for its Category 1 new drug, Ganovo (also known as Danoprevir or ASC08) to treat viral hepatitis C. more

News

STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec has announced that its active pharmaceutical ingredient (API) R&D and manufacturing facility in Changzhou, China, has passed its first inspection by the US Food and Drug Administration (FDA). more

News

STA Pharmaceuticals (a subsidiary of WuXi AppTec) has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D centre, aimed at strengthening the company’s pharma development and manufacturing platform. more

News

STA Pharmaceutical, a WuXi AppTec company, has signed an oligonucleotide synthesis collaboration agreement with biopharmaceutical company, Regulus Therapeutics, for research and mid-scale non-GMP/cGMP manufacturing. more

News

STA Pharmaceutical has reported rapid growth in companies intending to market their products in China using it as a partner following the CFDA announcement of the Market Authorization Holder (MAH) pilot programme last year more

Analysis

As we reach the end of CPhI Worldwide, we have some more revelations and innovations that keep coming from the vast show floor here in Frankfurt Messe, enjoy and until next year tschüß! more

News

Small molecule pharmaceutical development and manufacturing capability and technology platform company, STA Pharmaceutical, has entered into a five-year supply agreement with oncology-focused biopharma company, TESARO. more

News

During a recent summit, co-organised by STA Pharmaceutical, the Shanghai Municipal FDA and the local government of the Jinshan District of Shanghai, the current state of the China Marketing Authorisation Holder (MAH) system was discussed. more

News